Orthocell Ltd (ASX:OCC, OTC:ORHHF) has welcomed a household Australian name to its board of directors – former Australian US Ambassador and Governor of Western Australia, Deputy Prime Minister,and Minister for both Defence and Finance, Kim Beazley.
Beazley will join OCC as an independent non-executive director, offering “unrivalled” experience engaging with partners in the US.
The company believes the former Deputy Prime Minister will be a key adviser in its efforts to secure priority clinical, regulatory and commercial activities for its regenerative medicine product portfolio internationally.
“World-class regenerative medicine”
“We are delighted to welcome Kim Beazley to the Orthocell board as we implement our board renewal program and drive global commercialisation efforts for our world-class regenerative medicine portfolio,” Orthocell chair John Van Der Wielen said.
“Kim Beazley has extensive experience representing both public and private interests for Australia – and is an invaluable advocate for Orthocell in the United States, the largest healthcare market in the world.
“We are on the cusp of bringing Remplir™, a truly transformative nerve repair device, to this market, which will include continued positive engagement with regulators, world-renowned leading clinicians and commercialisation partners.
“We look forward to working closely with Kim to support this work, which represents a significant achievement for Australia’s medical innovation sector.”
Expansive career
Beazley served as Ambassador to the United States of America between 2010 and 2016, and currently holds multiple advisory or consulting roles in the fields of business, technology, defence and policy.
At present his commercial service extends to chair of the Perth US Asia Centre Board; board member of Luerssen Australia; Senior Distinguished Fellow of the Australian Strategic Policy Institute; adviser to Lockheed Martin Australia; chair of the Council for the Australian War Memorial; and adviser to TG & Associates.
“I am honoured to join the Orthocell team at this pivotal time in its clinical and commercial development – a much-loved West Australian innovation success story,” incoming Orthocell non-executive director Kim Beazley said.
“I have enormous respect for the human impact of its regenerative medicine treatments and will be proud to extend the reach and impact of the company’s products with our key commercial collaborators for Australia in the United States.”